Tag: drug pricing

drug pricing

Legislative

Azar Says FDA Has Authority to Require List Prices in Drug Ads

Azar Says FDA Has Authority to Require List Prices in Drug Ads

June 13, 2018 – At a Senate Committee on Health, Education, Labor & Pensions hearing on drug pricing held yesterday, Department of Health and Human Services (HHS) Secretary Alex Azar told the committee that it is his belief that “we have the authority to require list price disclosure in TV ads,” as proposed in the […]

Read more

DTC Advertising

Debate over Listing Drug Prices in Ads Continues

Debate over Listing Drug Prices in Ads Continues

May 21, 2018 – Since the Trump administration presented its proposal to lower drug pricing on May 11, both the trade and mainstream media have been discussing whether one provision – a request that the Department of Health & Human Services evaluate the inclusion of drug prices in consumer ads – really has legs. In […]

Read more

CHC News

Gain Actionable Insights at Rising Leaders Conference on Healthcare Policy

Gain Actionable Insights at Rising Leaders Conference on Healthcare Policy

May 14, 2018 – Leaders and rising stars in the healthcare communications field – in advertising, marketing, medical communications, journal publishing and digital platforms – will get both information about what is going on in Washington healthcare policy and access to key Washington contacts at the Coalition for Healthcare Communication Rising Leaders Conference on Healthcare […]

Read more

Washington Focus

White House Plan to Lower Drug Prices Takes Incremental Approach

White House Plan to Lower Drug Prices Takes Incremental Approach

May 14, 2018 – President Donald Trump on Friday announced his blueprint to lower drug prices, but his initiatives were deemed “a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks,” by The Wall Street Journal. One of the more controversial items in Trump’s plan is a request that the Department […]

Read more

Regulatory/FDA

White House Drug Pricing Initiative Could Include Moves on Generics/Biosimilars, Demonstration Projects and an End to Part D Rebates, Rawson Says

White House Drug Pricing Initiative Could Include Moves on Generics/Biosimilars, Demonstration Projects and an End to Part D Rebates, Rawson Says

May 4, 2018 – A drug pricing initiative expected from the White House May 8 is likely to include a number of incremental steps on drug pricing to support a strategy that is trickling down from President Trump to Health & Human Services Secretary Alex Azar and FDA Commissioner Scott Gottlieb, M.D. This initiative may […]

Read more

Legislative

Oregon Transparency Bill Signed into Law

Oregon Transparency Bill Signed into Law

April 2, 2018 – An Oregon transparency bill introduced in February was signed into law March 13 by Oregon Gov. Kate Brown (D), requiring drug companies not only to report drug prices to the state annually, but also to report costs associated with developing and marketing their drugs. “The Oregon bill (HB 4005) is the […]

Read more

General

HHS’ Azar Lists Drug Pricing as One of Four Top HHS Priorities

HHS’ Azar Lists Drug Pricing as One of Four Top HHS Priorities

Feb. 20, 2018 – In President Donald J. Trump’s FY 2019 Budget, drug pricing is one of the top priorities for the Department of Health and Human Services (HHS), according to HHS Secretary Alex Azar. “The President’s budget makes investments and reforms that are vital to making our health and human services programs work for […]

Read more

Legislative

Congress Should Make Lowering Drug Prices a Top Priority, POLITICO-Harvard Poll Says

Congress Should Make Lowering Drug Prices a Top Priority, POLITICO-Harvard Poll Says

Oct. 2, 2017 – According to a recent poll conducted by POLITICO and Harvard T.H. Chan School of Public Health, 40 percent of those surveyed said that lowering prescription drug prices should be Congress’ number one priority for the remainder of 2017. Just 26 percent of the public stated that repealing and replacing Obamacare should […]

Read more

Washington Focus

Oh, the Burdens We Bear: Commentary by Jack Angel

Oh, the Burdens We Bear: Commentary by Jack Angel

By Jack Angel, Executive Director, Coalition for Healthcare Communication Education Foundation July 10, 2017 — Although the population of Washington, D.C., is 681,200 and the folks who control it are far fewer, what happens on this tiny sliver of land that Washington occupies influences both our country and the world. In the extreme, decisions made […]

Read more

Washington Focus

Executive Order Seeks Better Odds for Competitive Drug Pricing

Executive Order Seeks Better Odds for Competitive Drug Pricing

June 27, 2017 – A draft Executive Order from President Donald J. Trump indicates the administration may seek to “roll back regulations in pursuit of faster drug approvals, promoting drug competition and new payment models for federal health insurance programs,” according to CQ Roll Call. A CQ Roll Call article stated that some of the […]

Read more